๐๐๐ง๐ฎ๐๐ซ๐ฒ ๐๐๐ฐ๐ฌ ๐๐จ๐ฎ๐ง๐ ๐๐ฉ
๐ ๐๐๐ฎ๐ฌ๐๐ก + ๐๐จ๐ฆ๐ ๐๐๐ช๐ฎ๐ข๐ซ๐๐ฌ ๐๐ก๐ข๐ญ๐๐๐๐ฉ ๐๐ข๐จ๐ฌ๐๐ข๐๐ง๐๐๐ฌ & ๐๐ฏ๐ข๐๐๐๐ ๐๐๐๐ฎ๐ซ๐๐ฌ $207.5๐ ๐๐จ๐ซ ๐๐ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ
Bausch + Lomb has acquired Whitecap Biosciences, strengthening its clinical-stage pipeline with treatments for glaucoma and geographic atrophy (GA). Chief Medical Officer, Yehia Hashad MD expressed optimism about the potential of Whitecapโs investigational medicines to slow or even improve vision loss in these conditions, marking a significant step forward in ophthalmology.
Aviceda Therapeutics raised $207.5M in Series C funding to advance AVD-104, a promising GA treatment. The financing supports ongoing Phase 2b and 3 trials against avacincaptad pegol (IZERVAY). Patient enrolment concluded in September 2024, with key results expected in late 2025.
๐ค ๐๐๐ ๐๐ง๐๐ซ๐จ๐ง ๐๐๐ช๐ฎ๐ข๐ซ๐๐ฌ ๐๐ฑ๐ฎ๐ฅ๐๐ซ ๐๐จ๐ซ ๐๐๐ญ๐ข๐ง๐๐ฅ ๐๐ข๐ฌ๐จ๐ซ๐๐๐ซ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ
Regeneron has acquired Oxular, a UK-based company specializing in ocular delivery tech for retinal disorders. Oxular's lead candidate, OXU-001, uses a proprietary microcatheter for targeted dexamethasone delivery, potentially lasting up to one year. This acquisition bolsters Regeneronโs portfolio in retinal disease treatment.
๐ ๐๐ฉ๐ญ๐๐ ๐ซ๐ ๐๐ฑ๐ฉ๐๐ง๐๐ฌ ๐ข๐ง๐ญ๐จ ๐ญ๐ก๐ ๐๐๐ญ๐ก๐๐ซ๐ฅ๐๐ง๐๐ฌ
Optegra Eye Health Care has acquired a 51% stake in Iris Eye Clinics through a joint venture with Quadrum Capital. This expansion leverages Quadrumโs network, including Lens Online, the Netherlandsโ largest contact lens supplier. CEO Peter Byloos sees this as a key step into a dynamic eye care market.
๐ ๐๐ฌ๐ฌ๐ข๐ฅ๐จ๐ซ๐๐ฎ๐ฑ๐จ๐ญ๐ญ๐ข๐๐ ๐๐ฑ๐ฉ๐๐ง๐๐ฌ ๐ข๐ง ๐๐๐-๐๐๐๐ก ๐ฐ๐ข๐ญ๐ก ๐๐ฌ๐ฉ๐๐ง๐ฌ๐ข๐จ๐ง๐ ๐๐ซ๐จ๐ฎ๐ฉ ๐๐๐ช๐ฎ๐ข๐ฌ๐ข๐ญ๐ข๐จ๐ง
EssilorLuxottica is acquiring Italy-based Espansione Group, a leader in non-invasive medical devices for dry eye, ocular surface, and retinal diseases. This move strengthens its presence in med-tech and eye care innovation.
๐ข ๐๐โ๐ซ๐ ๐๐ญ๐ญ๐๐ง๐๐ข๐ง๐ ๐๐๐๐ 2025
Weโll be attending MIDO in Milan this week! If youโre hiring or seeking a new role in eyecare, please reach out to James Pickering.